
Ceapro Inc. Reports 2023 Third Quarter and Nine-Month Financial Results and Operational Highlights
– Product development focused on the production of powder formulations of oat beta glucan and avenanthramides for cosmeceuticals market – Technology development focused on the PGX pilot scale units – Q3 2023 sales of $2,619,000 vs $3,845,000 in Q3 2022; …